modelTriflusal
Extends from Pharmacolibrary.Drugs.ATC.B.B01AC18.
Information
| name: | Triflusal | |
| ATC code: | B01AC18 | route: | oral |
| compartments: | 1 | |
| dosage: | 600 | mg |
| volume of distribution: | 10.8 | L |
| clearance: | 1.42 | L/h |
| other parameters in model implementation | ||
Triflusal is an antiplatelet agent derived from salicylic acid, used to prevent thromboembolic events in patients at risk of stroke or myocardial infarction, particularly in those with intolerance to acetylsalicylic acid. It acts mainly by inhibiting platelet aggregation. Although once widely used in several countries, it is currently not approved in the United States or many other regions.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), age range 18–64 years.
References
Park, SM, et al., & Han, S (2014). Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. BMC pharmacology & toxicology 15 75–None. DOI:10.1186/2050-6511-15-75 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25534747
Lee, HW, et al., & Yoon, YR (2011). A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Expert opinion on drug metabolism & toxicology 7(12) 1471–1479. DOI:10.1517/17425255.2011.630661 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22098139
Wang, M, et al., & Zhou, W (2014). Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. Drug research 64(5) 263–268. DOI:10.1055/s-0033-1357180 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24105106
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)